Published in Cancer Immunol Immunother on April 05, 2011
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology (2014) 1.28
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 1.07
Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother (2013) 1.06
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 0.94
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol (2013) 0.87
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun (2013) 0.87
Immunotherapies: the blockade of inhibitory signals. Int J Biol Sci (2012) 0.82
The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. Oncoimmunology (2013) 0.81
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother (2011) 0.80
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer (2014) 0.80
Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis. Int J Clin Exp Med (2015) 0.79
Tissue biomarkers in melanoma patients treated with TIL. PLoS One (2012) 0.79
Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. Am J Cancer Res (2016) 0.78
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer (2013) 0.77
Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Ther (2014) 0.77
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncoimmunology (2016) 0.75
Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase. Thyroid (2016) 0.75
Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients. Sci Rep (2016) 0.75
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology (2015) 0.75
Increased infiltration and tolerised antigen-specific CD8(+) TEM cells in tumor but not peripheral blood have no impact on survival of HCMV(+) glioblastoma patients. Oncoimmunology (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med (2006) 3.26
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev (2007) 3.15
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol (2003) 1.78
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy (2009) 1.21
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther (2007) 1.18
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer (2005) 1.18
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res (2009) 1.11
Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer (2010) 1.11
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun (2009) 1.09
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer (2006) 0.86
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol (2007) 3.25
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol (2004) 3.12
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2011) 2.80
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res (2003) 2.62
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 2.53
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell (2012) 2.50
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37